Part D/Prescription Drugs – Page 50 – medicarereport.org

Friday, September 11, 2026

Latest:

Alzheimer’s/Dementia FDA Part D/Prescription Drugs

Eileen Cook May 4, 2023May 4, 2023 Alzheimer’s Disease, Donanemab, Experimental Alzheimer’s Drug, FDA

Eli Lilly says an experimental drug slows Alzheimer’s worsening

(Source -The Associated Press published May 4, 2023 by NPR) WASHINGTON — Eli Lilly and Co. said Wednesday its experimental

Alzheimer’s/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

Eileen Cook May 3, 2023May 3, 2023 Alzheimer’s Disease, Alzheimer’s Treatment, CMS, FDA, medicare

26 state attorneys general urge Medicare to cover Alzheimer’s treatments

(By Rylee Wilson for Becker’s Hospital Review ) Twenty-six state attorneys general are asking Medicare to cover monoclonal antibody treatments

CMS Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook May 2, 2023May 2, 2023 CMS, medicare, Medicare Advantage, Medicare Part D

Half of All Eligible Medicare Beneficiaries Are Now Enrolled in Private Medicare Advantage Plans

(By Jeannie Fuglesten Biniek, Meredith Freed, Anthony Damico, and Tricia Neuman for Kaiser Family Foundation published May 01, 2023) According

Health Care Finance Medicare Advantage Part D/Prescription Drugs

Eileen Cook May 1, 2023May 1, 2023 Healthcare Costs, Medicare Advantage, Medicare Part D

More enrollees choosing higher-premium Medicare Advantage, Part D plans

(Rylee Wilson for Becker’s Hospital Review ) The average premium cost for Medicare Advantage plans sold on eHealth increased from

Health Care Finance Part D/Prescription Drugs

Eileen Cook April 27, 2023April 27, 2023 AHA, AHIP, PBM, Specialty Drugs

AHIP, AHA point fingers on cost of specialty drugs

(By Rylee Wilson for Becker’s Hospital Review ) Insurer groups say hospitals are to blame for higher costs of specialty

Health Care Finance Part D/Prescription Drugs

Eileen Cook April 26, 2023April 26, 2023 Drug spending, Healthcare Finance, Nonfederal Hospitals

Hospitals will spend up to 3% more on drugs in 2023, study finds

(By Paige Twenter for Becker’s Hospital Review ) Nonfederal hospitals’ costs have hovered around $35 billion to $40 billion since

Alzheimer’s/Dementia CMS Part D/Prescription Drugs

Eileen Cook April 25, 2023April 25, 2023 Alzheimer’s Disease, CMS, Donanemab, medicare

Medicare to cover new Alzheimer’s drugs, Eli Lilly says

(By Jakob Emerson for Becker’s Hospital Review ) Eli Lilly is expecting CMS to reverse course on its Medicare coverage

CMS Health Care Finance Health Care Redesign Legislative Update Medicare - General Part D/Prescription Drugs

Eileen Cook April 21, 2023April 21, 2023 CMS, Healthcare Finance, Inflation Reduction Act of 2022, medicare, Medicare Drug Price Negotiation Program, Medicare Part D

FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program

(By Juliette Cubanski for Kaiser Family Foundation Published: Apr 20, 2023) The Inflation Reduction Act of 2022 (the Act), signed

CMS Health Care Finance Part D/Prescription Drugs

Eileen Cook April 21, 2023April 21, 2023 CMS, medicare, Medicare Drug Price Negotiation Program, Pharma

Medicare drug pricing proposal not true negotiation, pharma group says

(By Rylee Wilson for Becker’s Hospital Review ) Pharmaceutical Research and Manufacturers of America says CMS’ guidance for Medicare drug

Health Care Finance Health Care Redesign Health Insurance Legislative Update Part D/Prescription Drugs

Eileen Cook April 21, 2023April 21, 2023 Healthcare Finance, Insulin, legislative update, Senators

Key senators make a big pivot on bipartisan insulin cost proposal

(By Rachel Cohrs for ST A T) WASHINGTON — Amid a scramble to assemble a health care policy package in